Myelodysplastic syndromes, version 2.2015.

Published

Journal Article

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

Full Text

Duke Authors

Cited Authors

  • Greenberg, PL; Stone, RM; Bejar, R; Bennett, JM; Bloomfield, CD; Borate, U; De Castro, CM; Deeg, HJ; DeZern, AE; Fathi, AT; Frankfurt, O; Gaensler, K; Garcia-Manero, G; Griffiths, EA; Head, D; Klimek, V; Komrokji, R; Kujawski, LA; Maness, LJ; O'Donnell, MR; Pollyea, DA; Scott, B; Shami, PJ; Stein, BL; Westervelt, P; Wheeler, B; Shead, DA; Smith, C; National comprehensive cancer network,

Published Date

  • March 2015

Published In

Volume / Issue

  • 13 / 3

Start / End Page

  • 261 - 272

PubMed ID

  • 25736003

Pubmed Central ID

  • 25736003

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0038

Language

  • eng

Conference Location

  • United States